The landscape of generic drug economics in the United States is undergoing a significant transformation, largely driven by the advent…
Read More
How most-favored-nation pricing is reshaping generic drug economics, according to Dr. Reddy’s finance director
The United States, long an outlier in global pharmaceutical pricing, is undergoing a profound transformation in its drug cost landscape,…
Read More
How most-favored-nation pricing is reshaping generic drug economics, according to Dr. Reddy’s finance director
The U.S. pharmaceutical landscape, historically characterized by higher drug prices compared to other developed nations, is undergoing a significant transformation,…
Read More
How most-favored-nation pricing is reshaping generic drug economics, according to Dr. Reddy’s finance director
The United States healthcare system, grappling with persistently high drug costs, has seen significant shifts in its economic landscape, particularly…
Read More
The Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals Plummet
On May 12, 2025, a significant executive order signed by then-US President Donald Trump mandated the US Department of Health…
Read More
